Several new orally effective diuretic agents, most of which represent slight chemical modifications of chlorothiazide, have been made available to the physician since the therapeutic usefulness of the parent compound was demonstrated. Two of these, Flumethiazide (Ademol) and Bendroflumethiazide (Naturetin) have recently been evaluated by the Council on Drugs. Both of these compounds contain the trifluoromethyl group in place of the chlorine atom of chlorothiazide. In addition, bendroflumethiazide is a hydrogenated derivative that resembles hydrochlorothiazide, but it also contains a benzyl group in the 3-position of the benzothiadiazine nucleus. These chemical modifications are small, but they alter the pharmacological activity of the compounds quantitatively, although not qualitatively.
These fluoro-derivatives have been used with satisfactory results in the treatment of edema associated with congestive heart failure, nephrosis, cirrhosis of the liver, corticosteroid therapy, toxemia of pregnancy, and the premenstrual period. Although clinical experience with these newer agents is more limited than
New Drugs and Developments in Therapeutics: A Council on Drugs' Digest. JAMA. 1961;176(2):138–139. doi:10.1001/jama.1961.63040150003013
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: